Karen B.L. Barlow

The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat

Sridhar Natesan, Kjell Svensson, Greg E. Reckless et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 77 citations

Distinct effects of sleep deprivation on binding to norepinephrine and serotonin transporters in rat brain

Débora Cristina Hipólide, Karin Di Monteiro Moreira, Karen B.L. Barlow et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2004 · 68 citations

Sleep, Neurophysiology, Neuroanatomy +12

The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist

Sridhar Natesan, Greg E. Reckless, Karen B.L. Barlow et al. · Psychopharmacology · 2008 · 56 citations

Molecular Pharmacology, Psychoactive Drug, Psychiatry +9

Evaluation of N-Desmethylclozapine as a Potential Antipsychotic—Preclinical Studies

Sridhar Natesan, Greg E. Reckless, Karen B.L. Barlow et al. · Neuropsychopharmacology · 2006 · 50 citations · Full text

Psychiatry, Medicine, Psychotropic Medication +6

Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models

Sridhar Natesan, Greg E. Reckless, Karen B.L. Barlow et al. · The International Journal of Neuropsychopharmacology · 2010 · 27 citations · Full text

Neuropsychology, Psychopharmacology, Pharmacotherapy +18